50 citations
,
July 2021 in “Nature Communications” This study found that the antiandrogen drug enzalutamide reduced TMPRSS2 levels and significantly decreased SARS-CoV-2 entry and infection in lung cells, supporting further clinical trials for COVID-19 treatment.
2 citations
,
June 2020 in “Research Square (Research Square)” This study demonstrated that the antiandrogen drug enzalutamide may reduce TMPRSS2 levels in human lung cells and mouse lungs, supporting its potential as a COVID-19 treatment option.
1 citations
,
January 2021 in “Research Square (Research Square)” This study found that the antiandrogens enzalutamide and bicalutamide reduced SARS-CoV-2 entry and infection in human lung cells by lowering TMPRSS2 levels, suggesting their potential as COVID-19 treatments and supporting clinical trials.
July 2024 in “Reactions Weekly” 1 citations
,
September 2025 in “The Yale Journal of Biology and Medicine” This essay explores the similarities in long-term health impacts of the COVID-19 and 1918 influenza pandemics, emphasizing how understanding medical history can guide better responses to post-epidemic health issues.